Articles related to GUIDELINES/RECOMMENDATIONS

Healthline reports that updated ACOG guidance strongly supports hormone therapy for vasomotor symptoms and related sleep disturbance in eligible patients. Nonhormonal options also receive strong recommendations; evidence remains insufficient for hormone therapy targeting depressive symptoms.

A hospitalist review of updated AHA resuscitation guidance highlights changes involving cardioversion energy, vascular access, POCUS, postarrest oxygen and temperature targets, medication use, and ethical decision-making during resuscitation.

The revised McDonald criteria recognize the cerebrospinal fluid κFLC index as an alternative to oligoclonal bands for demonstrating intrathecal immunoglobulin synthesis, expanding laboratory options while preserving the need for integrated MS diagnosis.

An international guideline recommends a more structured, phenotype-driven approach to genetic testing in children with short stature, identifying clinical characteristics that increase diagnostic yield while outlining when testing is and is not warranted.

ACP places estrogen-based therapy first in its pharmacologic pathway for menopausal vasomotor symptoms, with nonhormonal alternatives for contraindications or intolerance. Recommendation strength and evidence certainty vary, and long-term safety evidence remains limited.

The American Heart Association has updated infective endocarditis guidance to incorporate the 2023 Duke/ISCVID diagnostic criteria, advanced microbiologic diagnostics, contemporary imaging recommendations, and evolving antimicrobial treatment approaches while emphasizing multidisciplinary management.